Management of adverse renal events related to alemtuzumab treatment in multiple sclerosis: a Belgian consensus
Crossref DOI link: https://doi.org/10.1007/s13760-017-0864-x
Published Online: 2017-11-30
Published Print: 2018-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Sprangers, Ben http://orcid.org/0000-0003-1314-9675
Decoo, D.
Dive, D.
Lysandropoulos, A.
Vanopdenbosch, L.
Bovy, C.
License valid from 2017-11-30